Neerav Shukla, Rachel Kobos, Thomas Renaud, Julie Teruya-Feldstein, Anita Price, Linda McAllister-Lucas and Peter Steinherz Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab Cancer 118
Version of Record online: 13 DEC 2011 | DOI: 10.1002/cncr.26712
The authors report 2 patients who have long-term disease-free survival after receiving single-agent alemtuzumab therapy for refractory, metastatic histiocytic sarcoma. Patients with unresectable and metastatic histiocytic sarcoma should have tumor tissue tested for CD52 expression and should be considered for alemtuzumab therapy if they are CD52-positive.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field